Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
71 hedge funds and large institutions have $167M invested in Repare Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 25 reducing their positions, and 4 closing their positions.
383% more call options, than puts
Call options by funds: $145K | Put options by funds: $30K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
3% more funds holding
Funds holding: 69 → 71 (+2)
2.49% less ownership
Funds ownership: 86.68% → 84.19% (-2.5%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
36% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 25
37% less capital invested
Capital invested by funds: $267M → $167M (-$99.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$433K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$299K |
| 3 |
D.E. Shaw & Co
New York
|
+$275K |
| 4 |
Two Sigma Investments
New York
|
+$264K |
| 5 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$263K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.38M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.98M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$849K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$755K |
| 5 |
Morgan Stanley
New York
|
-$293K |
RPTX Hedge Fund Activity: Q1 2024 in Review
71 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q1 2024, worth a combined $167M — down 37% from $267M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RPTX positions and 4 closed out — a net gain of 2 holders — while 16 added to existing stakes and 25 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $433K. The largest seller was Logos Global Management, exiting entirely with an estimated $4.38M sold.
- 71 institutional investors held Repare Therapeutics (RPTX) as of Q1 2024, up from 69 in Q4 2023.
- Funds reported $167M of Repare Therapeutics stock for Q1 2024, down 37% quarter-over-quarter.
- 6 funds opened new Repare Therapeutics positions in Q1 2024 and 4 closed out, a net change of +2 holders.
- The largest Repare Therapeutics buyer in Q1 2024 was Opaleye Management, an estimated $433K added.
- The largest Repare Therapeutics seller in Q1 2024 was Logos Global Management, an estimated $4.38M sold.
Based on aggregated 13F filings for Q1 2024.